SPY382.39-7.07 -1.82%
DIA307.41-5.02 -1.61%
IXIC11,105.23-283.26 -2.49%

Galmed Pharmaceuticals Q4 EPS $(0.30), Inline

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. This is a 37.5 percent increase over losses of $(0.48) per share from the same period last year.

Benzinga · 05/02/2022 07:25

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. This is a 37.5 percent increase over losses of $(0.48) per share from the same period last year.